



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 09/13/2021 07:58
Last Report Issued 09/13/2021 07:58

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1876SP-POS
Patient ID 1876SP-POS
Chain 20002041
Age Not Given DOB Not Given
Gender Not Given
Workorder 20002041
Received 10/19/2020 13:25

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains drug screening results for Salicylates, Cannabinoids, Barbiturates, 6-Monoacetylmorphine, Acetyl Fentanyl, and Acryl Fentanyl.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Acryloylfentanyl, Alpha-Hydroxyetizolam, Alprazolam, Amlodipine, Cocaine, Fentanyl, Morphine, Phentermine, and Scope Statement.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table header with columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

Comment: The following is a general list of analyte classes included in this screen. The detection of any specific analyte is concentration-dependent. Note, not all known analytes in each specified analyte class are included. Some specific analytes outside of these classes are also included. For a detailed list of all analytes and reporting limits included in this screen, please contact NMS Labs. Amphetamines, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotic Agents, Benzodiazepines, CNS Stimulants, Cocaine and Metabolites, Hallucinogens, Hypnotics, Hypoglycemics, Muscle Relaxants, Non-Steroidal Anti-Inflammatory Agents, Opiates and Opioids.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50011SP Barbiturates Confirmation, Serum/Plasma

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Butalbital None Detected mcg/mL 0.20

A single oral 100 mg dose resulted in a mean peak blood concentration of 2.1 mcg/mL (range, 1.7 - 2.6 mcg/mL) at 2 hours, with a decline to 1.5 mcg/mL (range, 1.3 - 1.7 mcg/mL) by 24 hours. Potentially toxic at plasma concentrations greater than 10 mcg/mL.

Pentobarbital None Detected mcg/mL 0.20

Peak serum concentrations of 1.2 - 3.1 mcg/mL were produced 0.5 - 2.0 hours after a 100 mg oral dose and peak serum concentrations of 3 mcg/mL were produced 6 min. following a 100 mg IV dose. Potentially toxic at blood concentrations greater than 10 mcg/mL.

Secobarbital None Detected mcg/mL 0.20

Synonym(s): Seconal®
A 3.3 mg/kg oral dose (approx. 230 mg/70 kg) produced a mean peak blood concentration of 2.0 mcg/mL (range, 1.8 - 2.2 mcg/mL) at 3 hours, diminishing to 1.3 mcg/mL by 20 hours and 0.8 mcg/mL by 40 hours. Potentially toxic at blood concentrations greater than 8 mcg/mL.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Phenobarbital Synonym(s): Luminal® Serum/plasma concentrations of 10 - 30 mcg/mL are generally considered desirable when given as an anticonvulsant.	None Detected	mcg/mL	0.50	
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.				
50012SP Benzodiazepines Confirmation, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Diazepam Synonym(s): Valium® Therapeutic range: 100 - 1000 ng/mL.	None Detected	ng/mL	20	
Nordiazepam Synonym(s): Chlordiazepoxide Metabolite Psychiatric patients taking chronic diazepam doses ranging from 2 to 55 mg daily had steady state plasma concentrations of nordiazepam averaging 390 ng/mL (range 26 to 1600 ng/mL).	None Detected	ng/mL	20	
Oxazepam Synonym(s): Serax® When used as a drug, the therapeutic plasma concentration: 200 - 1400 ng/mL. Potentially toxic greater than 2000 ng/mL. As a metabolite of Diazepam, low concentrations may be observed. In one study, following chronic daily doses of about 70 mg of Diazepam, the steady-state serum concentrations were 50 - 400 ng Oxazepam/mL.	None Detected	ng/mL	20	
Temazepam Synonym(s): Normison®; Diazepam Metabolite	None Detected	ng/mL	20	

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Clobazam, Chlordiazepoxide, Lorazepam, Clonazepam, 7-Amino Clonazepam, Alprazolam, and Alpha-Hydroxyalprazolam.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Midazolam, Triazolam, Hydroxytriazolam, Hydroxyethylflurazepam, Desalkylflurazepam, and Flurazepam with their respective results and reporting limits.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): Dalmane® The mean peak plasma concentration following a 30 mg oral dose was 2.1 ng/mL at 1 hour post dose, but was undetectable at subsequent times.				
Estazolam	None Detected	ng/mL	5.0	
Synonym(s): ProSom® The mean peak plasma concentration following a 1 mg oral dose was 55 ng/mL (range, 40 - 70 ng/mL). The mean peak plasma concentration following a 2 mg oral dose was 98 ng/mL (range, 75 - 140 ng/mL).				
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.				
50013SP Cannabinoids Confirmation, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
11-Hydroxy Delta-9 THC	None Detected	ng/mL	1.0	
Synonym(s): Active Metabolite 11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.				
Delta-9 Carboxy THC	None Detected	ng/mL	5.0	
Synonym(s): Inactive Metabolite Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 10 - 101 ng/mL about 32 to 240 minutes after beginning smoking, with a slow decline. Usually not detectable after passive inhalation.				
Delta-9 THC	5.0	ng/mL	0.50	
Synonym(s): Active Ingredient of Marijuana Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.				

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table header with columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50014SP Cocaine and Metabolites Confirmation, Serum/Plasma

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Table with 4 columns: Analysis and Comments, Result, Units, Reporting Limit. Rows include Benzoylecgonine, Cocaine, and Cocaethylene with their respective results and reporting limits.

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Table with 4 columns: Analysis and Comments, Result, Units, Reporting Limit. Rows include Cocaine, Cocaethylene, and Benzoylecgonine with their respective results and reporting limits.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50016SP Opiates - Free (Unconjugated) Confirmation, Serum/Plasma

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Table with 4 columns: Analysis and Comments, Result, Units, Reporting Limit. Row includes Dihydrocodeine / Hydrocodol - Free with result None Detected and reporting limit 5.0.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52483SP Amphetamines Confirmation, Serum/Plasma

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

Table row for Ephedrine: Ephedrine, None Detected, ng/mL, 5.0

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
<p>A single 24 mg oral dose resulted in a peak plasma concentration of approximately 100 ng/mL.</p> <p>During chronic daily oral therapy with 15 mg (3 times daily), a plasma level of 95 ng/mL was reported at 4 hours, and 65 ng/mL at 6 hours after one 15 mg dose.</p>				
Pseudoephedrine	None Detected	ng/mL	5.0	
<p>Following a 60 mg oral dose (immediate-release tablet or syrup), mean peak plasma concentrations of 180 to 360 ng/mL were reported at 3 hours.</p> <p>Following a 120 mg oral dose (controlled-release capsule), mean peak plasma concentrations of 265 to 315 ng/mL were reported.</p> <p>Chronic administration of 360 mg/day (of a controlled-release preparation) resulted in mean steady-state plasma concentrations between 500 and 640 ng/mL over a 10-day period.</p>				
Phenylpropanolamine	None Detected	ng/mL	20	
<p>Synonym(s): Norephedrine; PPA</p> <p>Phenylpropanolamine is a drug as well as the metabolite of Ephedrine.</p> <p>Following a single 50 mg oral dose (immediate-release tablet), the mean peak plasma concentration was 180 ng/mL at 1 to 2 hours.</p> <p>Following a single 150 mg oral dose (sustained-release preparation), the mean peak plasma concentration was 280 ng/mL at 6 hours.</p>				
Norpseudoephedrine	None Detected	ng/mL	5.0	
<p>Synonym(s): Cathine</p> <p>Norpseudoephedrine is a metabolite of Pseudoephedrine.</p>				
Amphetamine	None Detected	ng/mL	5.0	
<p>Amphetamine is a drug as well as the metabolite of Methamphetamine.</p> <p>Therapeutic Range (treatment of Narcolepsy or Attention Deficit Disorder) with doses between 10 and 30 mg daily: Mean peak plasma concentrations between 35 and 110 ng/mL.</p>				

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Phentermine Synonym(s): Adipex-P®; Ionamin®; Pro-Fast® A single 26 mg/70 kg oral dose produced a mean peak blood concentration of 90 ng/mL at 4 hours, declining to 30 ng/mL after 40 hours. Adults receiving 30 mg daily oral doses for 2 weeks achieved a mean steady-state plasma concentration of 360 ng/mL (range 180 to 510 ng/mL).	None Detected	ng/mL	5.0	
Methamphetamine Therapeutic Range (treatment of Obesity and Attention Deficit Disorder) following a 12.5 mg oral dose: Mean peak blood concentrations were 20 ng/mL at 2.5 hours. This test reports Methamphetamine as the total of the undifferentiated d and l enantiomers. The ratio of these enantiomers is important in determining whether the source of Methamphetamine is from over the counter medications, prescribed medication or controlled substances. Call lab for further information on d to l enantiomer ratio determination.	None Detected	ng/mL	5.0	
MDA Synonym(s): 3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite MDA is a metabolite of MDMA and methylenedioxyethylamphetamine (MDEA) and is abused for its central nervous system stimulant and hallucinogenic properties. The peak concentration of the MDA metabolite following a 110 mg dose of MDMA was reported as 28 ng/mL at 4 hours.	None Detected	ng/mL	5.0	
MDMA Synonym(s): 3,4-Methylenedioxymethamphetamine; Ecstasy Following a single 50 mg oral dose, the mean peak plasma concentration was 110 ng/mL at 2 hours.	None Detected	ng/mL	5.0	
MDEA Synonym(s): 3,4-methylenedioxyethylamphetamine; Eve	None Detected	ng/mL	5.0	

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

A single oral 140 mg dose given to 6 adults produced peak plasma concentrations that averaged 260 ng/mL at 2.2 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52484SP Fentanyl and Acetyl Fentanyl Confirmation, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Fentanyl	10	ng/mL	0.10	
----------	----	-------	------	--

Synonym(s): Sublimaze®; Duragesic®

Immediately following a single 2 mcg/kg I.V. dose: Up to 11 ng/mL, declining to 1 ng/mL after one hour. Following the application of a 100 mcg/hour transdermal patch, serum levels (after an initial lag time of approximately six hours) of 0.8 - 2.6 ng/mL were maintained for more than 24 hours after application. Peak plasma levels following a single oral transmucosal dose (Fentanyl Oralet) of 15 mcg/kg to children: 2 - 4 ng/mL at 20 minutes. Substance(s) known to interfere with the identity and/or quantity of the reported result: 4-methylphenethyl acetyl fentanyl

Norfentanyl	None Detected	ng/mL	0.20	
-------------	---------------	-------	------	--

Synonym(s): Fentanyl Metabolite

Substance(s) known to interfere with the identity and/or quantity of the reported result: Benzyl Fentanyl

Acetyl Fentanyl	None Detected	ng/mL	0.10	
-----------------	---------------	-------	------	--

Acetyl fentanyl is a novel non-prescription synthetic opioid that has been implicated in several deaths.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52493SP Designer Benzodiazepines Confirmation, Serum/Plasma

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains entries for Bromazepam, Clonazepam, and Flubromazolam.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains two rows of data for Etizolam and Flubromazepam, including detailed analysis comments and reporting limits.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Delorazepam, Alpha-Hydroxyetizolam, and Diclazepam with detailed descriptions and results.

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
<p>3 hours. Diclazepam is metabolized to the active compounds delorazepam (chlordesmethyldiazepam), lormetazepam and lorazepam. Diclazepam may be detected in serum for at least to 4 days after use. The reported half-life is 42 hours.</p> <p>The blood to serum/plasma ratio is not known.</p> <p>This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.</p>				
<p>52500SP Designer Opioids Confirmation, Serum/Plasma</p> <p>Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)</p>				
Acryl Fentanyl Synonym(s): Acryloylfentanyl Acrylfentanyl is a novel non-prescription synthetic opioid.	None Detected	ng/mL	0.050	
2-Furanylfentanyl Synonym(s): Fu-F; Furanylfentanyl 2-Furanylfentanyl is a novel non-prescription synthetic opioid.	None Detected	ng/mL	0.050	
U-47700 Synonym(s): U-4 U-47700 is a novel non-prescription synthetic opioid.	None Detected	ng/mL	0.050	
Carfentanil Synonym(s): Carfantanyl; Wildnil® Carfentanil is an opioid analgesic used to immobilize large animals. It is not approved for human use.	None Detected	ng/mL	0.050	
Butyrylfentanyl Synonym(s): Butyrfentanyl Butyrylfentanyl is a novel non-prescription synthetic opioid.	None Detected	ng/mL	0.050	
para-Fluoroisobutyrylfentanyl	None Detected	ng/mL	0.050	

Results for sample 20002041-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20002041-001
Matrix Serum or Plasma
Patient Name 1876SP-POS
Patient ID 1876SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): 4F-Isobutyrylfentanyl; FIBF FIBF is a novel non-prescription synthetic opioid.				
cis-3-Methylfentanyl Cis-3-Methylfentanyl is a novel non-prescription synthetic opioid. Cis-3-methylfentanyl is typically found in combination with its isomer, trans-3-methylfentanyl.	None Detected	ng/mL	0.050	
Cyclopropylfentanyl Cyclopropylfentanyl is a novel non-prescription synthetic opioid. Substance(s) known to interfere with the identity and/or quantity of the reported result: Crotonyl fentanyl impurity	None Detected	ng/mL	0.050	
trans-3-Methylfentanyl Trans-3-Methylfentanyl is a novel non-prescription synthetic opioid. Trans-3-methylfentanyl is typically found in combination with its isomer, cis-3-methylfentanyl. Substance(s) known to interfere with the identity and/or quantity of the reported result: crotonyl fentanyl	None Detected	ng/mL	0.050	
Valeryl Fentanyl Synonym(s): Pentylfentanyl Valeryl fentanyl is a novel non-prescription synthetic opioid.	None Detected	ng/mL	0.050	

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.